|
1
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shibutani M, Maeda K, Nagahara H, Noda E,
Ohtani H, Nishiguchi Y and Hirakawa K: A high preoperative
neutrophil-to-lymphocyte ratio is associated with poor survival in
patients with colorectal cancer. Anticancer Res. 33:3291–3294.
2013.PubMed/NCBI
|
|
4
|
Absenger G, Szkandera J, Stotz M,
Postlmayr U, Pichler M, Ress AL, Schaberl-Moser R, Loibner H,
Samonigg H and Gerger A: Preoperative neutrophil-to-lymphocyte
ratio predicts clinical outcome in patients with stage II and III
colon cancer. Anticancer Res. 33:4591–4594. 2013.PubMed/NCBI
|
|
5
|
Shibutani M, Maeda K, Nagahara H, Iseki Y,
Ikeya T and Hirakawa K: Prognostic significance of the preoperative
lymphocyte-to-monocyte ratio in patients with colorectal cancer.
Oncol Lett. 13:1000–1006. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo YH, Sun HF, Zhang YB, Liao ZJ, Zhao L,
Cui J, Wu T, Lu JR, Nan KJ and Wang SH: The clinical use of the
platelet/lymphocyte ratio and lymphocyte/monocyte ratio as
prognostic predictors in colorectal cancer: A meta-analysis.
Oncotarget. 8:20011–20024. 2017.PubMed/NCBI
|
|
7
|
Liu Y, He X, Pan J, Chen S and Wang L:
Prognostic role of Glasgow prognostic score in patients with
colorectal cancer: Evidence from population studies. Sci Rep.
7:61442017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kishiki T, Masaki T, Matsuoka H, Kobayashi
T, Suzuki Y, Abe N, Mori T and Sugiyama M: Modified Glasgow
prognostic score in patients with incurable stage IV colorectal
cancer. Am J Surg. 206:234–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z
and Xu J: Systemic inflammation score predicts postoperative
prognosis of patients with clear-cell renal cell carcinoma. Br J
Cancer. 113:626–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suzuki Y, Okabayashi K, Hasegawa H,
Tsuruta M, Shigeta K, Kondo T and Kitagawa Y: Comparison of
preoperative inflammation-based prognostic scores in patients with
colorectal cancer. Ann Surg. 267:527–531. 2018.PubMed/NCBI
|
|
11
|
Eltohami YI, Kao HK, Lao WW, Huang Y,
Abdelrahman M, Liao CT, Yen TC and Chang KP: The prediction value
of the systemic inflammation score for oral cavity squamous cell
carcinoma. Otolaryngol Head Neck Surg. Jan 1–2018.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cassidy J, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Randomized phase III study of capecitabine plus
oxaliplatin compared with fluorouracil/folinic acid plus
oxaliplatin as first-line therapy for metastatic colorectal cancer.
J Clin Oncol. 26:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamada Y, Takahari D, Matsumoto H, Baba H,
Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y,
et al: Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab
versus S-1 and oxaliplatin plus bevacizumab in patients with
metastatic colorectal cancer (SOFT): An open-label,
non-inferiority, randomised phase 3 trial. Lancet Oncol.
14:1278–1286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McMillan DC, Elahi MM, Sattar N, Angerson
WJ, Johnstone J and McArdle CS: Measurement of the systemic
inflammatory response predicts cancer-specific and non-cancer
survival in patients with cancer. Nutr Cancer. 41:64–69. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nazha B, Moussaly E, Zaarour M,
Weerasinghe C and Azab B: Hypoalbuminemia in colorectal cancer
prognosis: Nutritional marker or inflammatory surrogate? World J
Gastrointest Surg. 7:370–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dunn GP, Old LJ and Schreiber RD: The
immunobiology of cancer immunosurveillance and immunoediting.
Immunity. 21:137–148. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shibutani M, Maeda K, Nagahara H, Ohtani
H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Tanaka H,
et al: Prognostic significance of the lymphocyte-to-monocyte ratio
in patients with metastatic colorectal cancer. World J
Gastroenterol. 21:9966–9973. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cézé N, Thibault G, Goujon G, Viguier J,
Watier H, Dorval E and Lecomte T: Pre-treatment lymphopenia as a
prognostic biomarker in colorectal cancer patients receiving
chemotherapy. Cancer Chemother Pharmacol. 68:1305–1313. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Condeelis J and Pollard JW: Macrophages:
Obligate partners for tumor cell migration, invasion, and
metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leek RD and Harris AL: Tumor-associated
macrophages in breast cancer. J Mammary Gland Biol Neoplasia.
7:177–189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qian BZ and Pollard JW: Macrophage
diversity enhances tumor progression and metastasis. Cell.
141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mantovani A, Bottazzi B, Colotta F,
Sozzani S and Ruco L: The origin and function of tumor-associated
macrophages. Immunol Today. 13:265–270. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pollard JW: Tumour-educated macrophages
promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paik KY, Lee IK, Lee YS, Sung NY and Kwon
TS: Clinical implications of systemic inflammatory response markers
as independent prognostic factors in colorectal cancer patients.
Cancer Res Treat. 46:65–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sugimoto K, Komiyama H, Kojima Y, Goto M,
Tomiki Y and Sakamoto K: Glasgow prognostic score as a prognostic
factor in patients undergoing curative surgery for colorectal
cancer. Dig Surg. 29:503–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Furukawa K, Shiba H, Haruki K, Fujiwara Y,
Iida T, Mitsuyama Y, Ogawa M, Ishida Y, Misawa T and Yanaga K: The
Glasgow prognostic score is valuable for colorectal cancer with
both synchronous and metachronous unresectable liver metastases.
Oncol Lett. 4:324–328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jia J, Zheng X, Chen Y, Wang L, Lin L, Ye
X, Chen Y, Chen D and Dettke M: Stage-dependent changes of
preoperative neutrophil to lymphocyte ratio and platelet to
lymphocyte ratio in colorectal cancer. Tumour Biol. 36:9319–9325.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shibutani M, Maeda K, Nagahara H, Ohtani
H, Sakurai K, Yamazoe A, Kimura K, Toyokawa T, Amano R, Kubo N, et
al: Significance of markers of systemic inflammation for predicting
survival and chemotherapeutic outcomes and monitoring tumor
progression in patients with unresectable metastatic colorectal
cancer. Anticancer Res. 35:5037–5046. 2015.PubMed/NCBI
|
|
30
|
Tanaka H, Muguruma K, Toyokawa T, Kubo N,
Ohira M and Hirakawa K: Differential impact of the
neutrophil-lymphocyte ratio on the survival of patients with stage
IV gastric cancer. Dig Surg. 31:327–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cedrés S, Torrejon D, Martínez A, Martinez
P, Navarro A, Zamora E, Mulet-Margalef N and Felip E: Neutrophil to
lymphocyte ratio (NLR) as an indicator of poor prognosis in stage
IV non-small cell lung cancer. Clin Transl Oncol. 14:864–869. 2012.
View Article : Google Scholar : PubMed/NCBI
|
